Inhibitory effects of interleukin-4 on human renal cell carcinoma cells in vitro: In combination with interferon-α, tumor necrosis factor-α or interleukin-2

International Journal of Urology

Volumn 3, Issue 3, 1996, Pages 196-201

  Cheon, Jun ^a   Chung, Dong Joon ^a   Kim, Je Jong ^a   Koh, Sung Kun ^a   Sohn, Jeongwon ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Growth inhibition; Human renal cell carcinoma cell line; Interferon 2b; Interleukin 4; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 4; RECOMBINANT ALPHA2B INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CARCINOMA CELL; CELL PROLIFERATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0029975490     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1996.tb00516.x     Document Type: Article

References (32)

1. Horoszewicz JS, Murphy GP. An assessment of interferon in urological cancer. J Urol 1989;142:1173-1178.
2. Milanese C, Richardson NER, Reinherz EL. Identification of T helper cell-mediated lymphokine that activates resting T-lymphocytes. Science 1990;231: 1118-1122.
3. Howard M, Farrar J, Hilfiker M, Johnson B, Takatsu K, Hamaoka T, Paul W. Identification of a T cell-derived B cell growth factor distinct from IL-2. J Exp Med 1982;155:914-923.
4. Yodota T, Arai N, deVries J, Spits H, Banchereau J, Zlotnik A, Rennick D, Howard M, Takabe Y, Niyatake S, Lee F, Arai K. Molecular biology of their products that stimulates B cells, T cells, and hematopoietic cells. Immunol Rev 1988;102:137-187.
5. Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli PS, A-Hamilton JA. Potential anti-inflammatory effects of interleukin-4: suppression of human monocyte, tumor necrosis factor, interleukin-1 and prostaglandin E2. Proc Natl Acad Sci USA 1989;86:3803-3807.
6. Lee JD, Swisher SG, Minehart EM, Mcbride WH, Economou JS. Interleukin-4 downregulates interleukin-6 production in human peripheral blood mononuclear cells. J Leukocyte Biol 1990;47:475-479.
7. Cao H, Wolff RG, Meltzer MS, Crawford RM. Differential regulation of class II MHC determinants on macrophages by IFN-γ and IL-4. J Immunol 1989;143: 3524-3531.
8. Littman BH, Dastvan FF, Carlson PL, Sanders KM. Regulation of monocyte/macrophage C2 production and HLA-DR expression by IL-4 and IFN-γ. J Immunol 1989;142:520-525.
9. Bosco M, Giovarelli M, Forni M, Modesti A, Scarpa S, Masuelli L, Forni G. Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J Immunol 1990;145:3136-3143.
10. Hoon DSB, Banez M, Okun E, Morton DL, Irie RF. Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor. Cancer Res 1991;51: 2002-2008.
11. Toi M, Bichnell R, Harris AL. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 1992;52:275-279.
12. 1 cell cycle progression in gastric carcinoma cells. Cancer Res 1994;54:1113-1118.
13. Taylor CW, Grogan TM, Salmon SE. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood 1990;75:1114-1118.
14. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1992;57:503-512.
15. Akashi K, Shibuya T, Harada M, Takamatsu Y, Uike N, Eto T, Niho Y. Interleukin-4 suppresses the spontaneous growth of chronic myelomonocytic leukemia cells. J Clin Invest 1991;88:223-230.
16. Hoon DSB, Okun E, Banez M, Irie RF, Morton DL. Interleukin-4 alone and with interferon or tumor necrosis factor inhibits cell growth and modulates cell surface antigen on human renal cell carcinomas. Cancer Res 1991;51:5687-5693.
17. Toi M, Harris AL, Bicknell R. Interleukin-4 is a potent mitogen for capillary endothelium. Biochem Biophys Res Commun 1991;174:1287-1293.
18. Idzerda RL, March CJ, Mosley B, Lyman SD, Bos TV, Gimpel SD, Din WS, Grabstein KH, Widmer MB, Park LS. Human interleukin-4 receptor confers biological responsiveness and defines a novel receptor super-family. J Exp Med 1990;171:861-873.
19. Puri RK, Ogata M, Leland D, Feldman GM, Fitzgerald D, Pastan I. Expression of high affinity interleukin-4 receptors on murine sarcoma cells and receptor mediated cytotoxicity of tumor cells to chimeric protein between interleukin-4 and Pseudomonas exotoxin. Cancer Res 1991;51:3011-3017.
20. Obiri NI, Hillman GG, Haas GP, Sud S, Puri RK. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest 1993;91:88-93.
21. Cheon J, Chung DJ, Choi JB, Koh SK, Sohn J. Interleukin-4 receptor expression on human renal cell carcinoma cell-lines by a reverse transcription-polymerase chain reaction. Korean J Urol 1995;36: 121-127.
22. Morisaki T, Uchiyama A, Yuzuki D, Essner R, Morton DL, Hoon DS. Interleukin 4 regulates G1 cell cycle progression in gastric carcinoma cells. Cancer Res 1994;54:1113-1118.
23. Fransen LF, Heyden J, Ruysschaert R, Fiers W. Recombinant tumor necrosis factor: its effect and its synergism with interferon-γ on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 1986;22:419-426.
24. Ruggiero V, Baglioni C. Synergistic anti-proliferative activity of interleukin 1 and tumor necrosis factor. J Immunol 1987;138:661-663.
25. Bono AV, Reali L, Benvenuti C, Rigatti P, Gibba A, Cosciani-Cunico S, Vicini D, Pavone-Macaluso M, Anselmo G, Coppi F, Franch L. Recombinant alpha interferon in metastatic renal cell carcinoma. Urology 1991;38:60-63.
26. Creagan ET, Twito DI, Johansson SL, Schaid DJ, Johnson PS, Flaum MA, Buroker TR, Geeroerto LH, Veeder MH, Gesme DH, Homburger HA. A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adeno carcinoma. J Clin Oncol 1991; 9:2104-2109.
27. Levens W, Ruebben H, Ingenhag W. Long-term interferon treatment in metastatic renal cell carcinoma. Eur Urol 1989;16:378-381.
28. Atzpodien J, Poliwoda H, Kirchner H. Alpha-interferon and interleukin-2 in renal cell carcinoma: studies in non-hospitalized patients. Semin Oncol 1991;18:108-112.
29. Figlin RA, Belldegrun A, Moldawer N, Zeffren J, deKernion J. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992;10: 414-421.
30. Pichert G, Jost LM, Fierz W, Stahel RA. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alpha-2a in patients with advanced renal cell carcinoma and melanoma. Br J Cancer 1991;63:287-292.
31. Lindemann A, Monson JRT, Stahel RA, Calabres F, Ludwig Ch, Decosier G, Mertelsmann R. Low intensity combination treatment with r-interleukin-2 (rh-IL-2) and r-interferon alpha-2a (rh-IFN-alpha-2A) in renal cell carcinoma: a multicemer phase II trial. Proc Am Soc Clin Oncol 1990;9:150(Abstract).
32. Aggarwal BB, Eessalu TE, Haas PE. Characterization of receptors for human tumor necrosis factor and their regulation by γ-interferon. Nature (Lond.) 1985;318: 665-667.